Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MorphoSys AG
Coming year could feature first-time approvals in the EU for at least five gene therapies.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Plus deals involving BioAtla/BeiGene, OliX/Thea, Chugai/Argenx, Shionogi/HanaVax, TaiGen/Luminairie, Novartis/1Yao.com, Sperogenix/Minoryx, Quantum/Orient EuroPharma and AtomWise/GC Pharma.
- Drug Discovery Tools
- Other Names / Subsidiaries
- Lanthio Pharma B.V.
- MorphoSys US Inc.
- Sloning BioTechnology